Warning: fopen(/home/stweet/public_html/components/com_stocksonline/cache/tweetCache/cache_NLTX_html) [function.fopen]: failed to open stream: Permission denied in /home/stweet/public_html/components/com_stocksonline/library/class.cache.php on line 66
Nile Therapeutics, Inc. - NLTX Insiders
No Insiders
We have no insiders for Nile rapeutics right now.
Know someone who is an insider on Nile Therapeutics, Inc.?
Let us know.
Nile Therapeutics, Inc. - NLTX information
We are a development stage biopharmaceutical company in the business of
commercially developing innovative products for the treatment of cardiovascular
diseases. Our lead compound is CD-NP, a chimeric natriuretic peptide currently
in Phase I clinical studies for the treatment of heart failure. We believe CD-NP
may be useful in several cardiovascular and renal indications. We are initially
developing CD-NP as a treatment for heart failure. We are also developing
2NTX-99, a pre-clinical, small molecule, anti-atherothrombotic agent with nitric
oxide (NO) donating properties.
We were incorporated in the State of Nevada on June 17, 1996 and reincorporated
in Delaware on February 9, 2007, at which time our name was SMI Products, Inc.,
or SMI. From inception through August 11, 2006, SMI was a development stage
company in the business of internet real estate mortgage services. On and after
August 11, 2006, SMI ceased its prior business. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f27%2f0001193125-08-067071.html#FIS_BUSINESS" ...
Founded in 1996
NILE THERAPEUTICS INC (NLTX:NASDAQ CM)
LAST $0.37 USD
CHANGE TODAY -0.0001 -0.03%
VOLUME 16.2K
As of 8:09 PM 07/30/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of NILE THERAPEUTICS INC (NLTX)
|
OPEN
$0.36
|
PREVIOUS CLOSE
$0.37
|
|
|
DAY HIGH
$0.37
|
DAY LOW
$0.35
|
|
|
52 WEEK HIGH
08/26/09 - $2.30
|
52 WEEK LOW
07/7/10 - $0.29
|
|
|
MARKET CAP
12.8M
|
AVERAGE VOLUME 10 D
96.5K
|
|
|
EPS TTM
$-0.31
|
SHARES OUTSTANDING
34.6M
|
|
|
NLTX Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
NLTX Competitors
| Company | Last | Change | |
| No competitor information is available for NLTX. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | NLTX | Industry Range |
| No financial data is available for NLTX. | ||
|
NLTX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Nile Therapeutics, Inc. - NLTX news
NILE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vot
2010-07-28 09:22:39
Quote: Read article
Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
2010-07-23 06:08:25
Keywords: Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors, nltx
Quote: Read article
NILE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
2010-07-15 01:21:05
Quote: Read article
Nile Therapeutics Completes Dosing of Phase II Study
2010-07-08 03:46:14
Keywords: Nile Therapeutics Completes Dosing of Phase II Study, nltx
Quote: Read article
NILE THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta
2010-06-07 06:10:44
Quote: Read article
Nile Therapeutics Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
2010-06-04 08:12:00
Keywords: Nile Therapeutics Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule, nltx
Quote: Read article
Nile Therapeutics Reports 2010 First Quarter Financial Results
2010-05-17 07:10:38
Keywords: Nile Therapeutics Reports 2010 First Quarter Financial Results, nltx, earnings
Quote: Read article
Nile Therapeutics Announces Exercise of Over-Allotment Option for Recent Public Offering
2010-05-11 03:34:20
Keywords: Nile Therapeutics Announces Exercise of Over-Allotment Option for Recent Public Offering, nltx,nltxw
Quote: Read article
Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
2010-05-10 01:53:57
Keywords: Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study, nltx
Quote: Read article
Nile Therapeutics Announces Closing of Public Offering
2010-04-28 07:50:42
Keywords: Nile Therapeutics Announces Closing of Public Offering, nltx,nltxw
Quote: Read article
Nile Therapeutics Announces Pricing of Public Offering
2010-04-23 06:12:22
Keywords: Nile Therapeutics Announces Pricing of Public Offering, nltx
Quote: Read article
NILE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhi
2010-04-23 06:12:21
Quote: Read article
Nile Therapeutics Reports 2009 Fourth Quarter and Full Year Financial Results
2010-03-05 07:31:06
Quote: Read article
Nile Therapeutics Reports 2009 Fourth Quarter and Full Year Financial Results
2010-03-04 03:10:53
Quote: Read article
Nile Therapeutics to Present at BIO CEO and Investor Conference
2010-03-01 01:04:47
Quote: Read article
NILE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
2010-02-15 08:08:54
Quote: Read article
Nile Therapeutics to Present at BIO CEO and Investor Conference
2010-02-05 07:37:20
Quote: Read article
Nile Therapeutics Reports 2009 Third Quarter Financial Results
2010-01-20 02:26:00
Quote: Read article